CA2435921C - Method of cancer therapy - Google Patents

Method of cancer therapy Download PDF

Info

Publication number
CA2435921C
CA2435921C CA002435921A CA2435921A CA2435921C CA 2435921 C CA2435921 C CA 2435921C CA 002435921 A CA002435921 A CA 002435921A CA 2435921 A CA2435921 A CA 2435921A CA 2435921 C CA2435921 C CA 2435921C
Authority
CA
Canada
Prior art keywords
compound
days
paclitaxel
formula
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002435921A
Other languages
English (en)
French (fr)
Other versions
CA2435921A1 (en
Inventor
Lars Holger Breimer
Kapil Dhingra
Urvashi Hooda Dhingra
Steve Ritland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2435921A1 publication Critical patent/CA2435921A1/en
Application granted granted Critical
Publication of CA2435921C publication Critical patent/CA2435921C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002435921A 2001-02-09 2002-02-01 Method of cancer therapy Expired - Lifetime CA2435921C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26787401P 2001-02-09 2001-02-09
US06/267,874 2001-02-09
PCT/EP2002/001042 WO2002064214A2 (en) 2001-02-09 2002-02-01 Anti cancer combination of substituted pyrroles and paclitaxel

Publications (2)

Publication Number Publication Date
CA2435921A1 CA2435921A1 (en) 2002-08-22
CA2435921C true CA2435921C (en) 2009-12-22

Family

ID=23020488

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002435921A Expired - Lifetime CA2435921C (en) 2001-02-09 2002-02-01 Method of cancer therapy

Country Status (17)

Country Link
US (1) US6548531B2 (https=)
EP (1) EP1359979B1 (https=)
JP (1) JP4128872B2 (https=)
KR (1) KR100542069B1 (https=)
CN (1) CN1265786C (https=)
AR (2) AR035429A1 (https=)
AT (1) ATE324145T1 (https=)
AU (1) AU2002246080B2 (https=)
BR (1) BR0206954A (https=)
CA (1) CA2435921C (https=)
DE (1) DE60210926T2 (https=)
DK (1) DK1359979T3 (https=)
ES (1) ES2261648T3 (https=)
MX (1) MXPA03007036A (https=)
PT (1) PT1359979E (https=)
WO (1) WO2002064214A2 (https=)
ZA (1) ZA200305967B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
JP2004532245A (ja) * 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
JP2004537515A (ja) * 2001-05-15 2004-12-16 フォーク ファーマシューティカルス，インク． ウィルス感染症治療用薬物のターゲッティング送達
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
CA2140653A1 (en) * 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
PT1064279E (pt) 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Also Published As

Publication number Publication date
WO2002064214A3 (en) 2003-05-30
AU2002246080C1 (en) 2002-08-28
ZA200305967B (en) 2005-01-26
CN1491126A (zh) 2004-04-21
ATE324145T1 (de) 2006-05-15
DK1359979T3 (da) 2006-08-28
AR098745A2 (es) 2016-06-08
MXPA03007036A (es) 2003-11-18
CN1265786C (zh) 2006-07-26
EP1359979A2 (en) 2003-11-12
PT1359979E (pt) 2006-08-31
WO2002064214A8 (en) 2004-02-19
BR0206954A (pt) 2004-02-25
US20020156118A1 (en) 2002-10-24
JP2004517961A (ja) 2004-06-17
KR20040025894A (ko) 2004-03-26
US6548531B2 (en) 2003-04-15
WO2002064214A2 (en) 2002-08-22
JP4128872B2 (ja) 2008-07-30
AR035429A1 (es) 2004-05-26
EP1359979B1 (en) 2006-04-26
DE60210926D1 (de) 2006-06-01
ES2261648T3 (es) 2006-11-16
AU2002246080B2 (en) 2006-08-10
CA2435921A1 (en) 2002-08-22
KR100542069B1 (ko) 2006-01-11
DE60210926T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
CA2435921C (en) Method of cancer therapy
Vokes et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
JP2003533485A5 (https=)
AU2002246080A1 (en) Method for Cancer Therapy
Kok et al. Cisplatin and etoposide in oesophageal cancer: a phase II study
US5824346A (en) Combination therapy for advanced cancer
ES2241639T3 (es) Terapia de combinacion que usa un compuesto de pentafluorobencensulfonamidas y platino.
Mayerhofer et al. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
EP0858341B1 (en) Combination therapy for advanced cancer comprising temozolomide and cisplatin
CN114470216B (zh) 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法
CA2465807A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
JPS63258414A (ja) 抗腫瘍剤
US20050079225A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
CN111407748A (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
Gupta Treatment of advanced gastric cancer with 5‐fluorouracil versus mitomycin C
RU2279277C2 (ru) Лечение разделенными дозами агентов с сосудоразрушающей активностью
Chewaskulyong et al. Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer
WO2002102373A1 (en) Method for administration of cancer therapeutic
EP1599210A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
MXPA98001585A (es) Terapia combinada para el cancer avanzado, que comprende la temozolomida y el cisplatin
HK40011479A (en) Method for administration of an anti-tumor agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220201